

DSP107 - Turning the Promise of Immunotherapy Into a Reality for Colorectal Cancer Patients

Yaron Pereg, Tomer Cohen Company name Kahr Medical Ltd. * Website www.Kahrbio.com * CEO name Yaron Pereg *

CATEGORY: Biotech/Pharma “Redefining the Fight Against Cancer: New Targets, New Modalities.”

- Executive Summary / Investment Rationale Kahr is a clinical-stage oncology company developing multi-functional dual-targeting fusion proteins that activate the innate and adaptive immune systems simultaneously to bolster anti-tumor activity in difficult to treat cancer patients. Our lead product, DSP107, is being tested in phase II studies under clinical collaboration with Roche. Topline efficacy results are expected during 2027. The company raised to date approx. \$150M.
- Core Technology We employ our Multi-Functional Immuno-Recruitment (MIRP) platform to design product candidates that have two distinct targeting domains. Our products target key receptors expressed on tumor and immune cells. The resulting fusion protein is tumor specific and capable of both unblocking immunosuppressive mechanisms while simultaneously activating and propagating key immune cells. This synergistic and tumor-localized activity ensures enhanced efficacy and safety.
- Product Profile/Pipeline DSP107 blocks CD47 on cancer cells and engages 4-1BB expressing cytotoxic T-cell to the tumor microenvironment. Phase II data demonstrated objective responses and extended survival in MSS colorectal cancer patients, a cold tumor that is nonresponsive to immunotherapy. Importantly, DSP107 has demonstrated excellent safety profile, no binding to RBCs and lack of hematological or hepato-toxicities differentiating it from other CD47 and 4-1BB agents.
- Business Strategy Our strategy is to be the first company to develop (i) a CD47 inhibitor approved for the treatment of solid tumors and (ii) an approved 4-1BB engager. If we are successful, we will be able to access the multibillion-dollar colorectal cancer market, with additional indications creating additional revenue opportunities afterwards.
- What's Next? We are currently testing DSP107 in a randomized controlled phase IIb study in metastatic late line colorectal cancer patients and plan to expand the clinical development of DSP107 and assess its potential in earlier lines. In preparation for a potential future phase III study, we plan to scale-up its manufacturing process